Cargando…
Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma
Tolinapant (ASTX660) is a potent, nonpeptidomimetic antagonist of cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) and X-linked IAP, which is currently being evaluated in a phase 2 study in T-cell lymphoma (TCL) patients. Tolinapant has demonstrated evidence of single-agent clinical activi...
Autores principales: | Ferrari, Nicola, Ward, George, Gewinner, Christina, Davis, Matthew P., Jueliger, Simone, Saini, Harpreet, Munck, Joanne, Smyth, Tomoko, Ferraldeschi, Roberta, Keer, Harold, Lyons, John, Sims, Martin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945623/ https://www.ncbi.nlm.nih.gov/pubmed/34474469 http://dx.doi.org/10.1182/bloodadvances.2020003955 |
Ejemplares similares
-
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023) -
Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
por: Dean, Erin A., et al.
Publicado: (2023) -
An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
por: Roider, Tobias, et al.
Publicado: (2021) -
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment
por: Bourne, Christopher M., et al.
Publicado: (2022) -
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)